×
S&P 500   3,816.93 (-0.22%)
DOW   30,864.58 (-0.75%)
QQQ   285.47 (+1.18%)
AAPL   141.21 (+1.64%)
MSFT   262.12 (+0.98%)
META   167.32 (+4.56%)
GOOGL   2,261.28 (+3.98%)
AMZN   113.59 (+3.68%)
TSLA   695.28 (+1.98%)
NVDA   148.86 (+2.50%)
NIO   22.04 (+3.18%)
BABA   118.48 (+2.14%)
AMD   74.77 (+1.49%)
MU   56.67 (+5.63%)
CGC   2.66 (-5.34%)
T   21.12 (-0.89%)
GE   61.74 (-2.83%)
F   11.11 (-1.86%)
DIS   96.98 (+0.87%)
AMC   12.62 (-6.73%)
PFE   51.34 (-1.85%)
PYPL   74.26 (+4.01%)
NFLX   184.41 (+2.48%)
S&P 500   3,816.93 (-0.22%)
DOW   30,864.58 (-0.75%)
QQQ   285.47 (+1.18%)
AAPL   141.21 (+1.64%)
MSFT   262.12 (+0.98%)
META   167.32 (+4.56%)
GOOGL   2,261.28 (+3.98%)
AMZN   113.59 (+3.68%)
TSLA   695.28 (+1.98%)
NVDA   148.86 (+2.50%)
NIO   22.04 (+3.18%)
BABA   118.48 (+2.14%)
AMD   74.77 (+1.49%)
MU   56.67 (+5.63%)
CGC   2.66 (-5.34%)
T   21.12 (-0.89%)
GE   61.74 (-2.83%)
F   11.11 (-1.86%)
DIS   96.98 (+0.87%)
AMC   12.62 (-6.73%)
PFE   51.34 (-1.85%)
PYPL   74.26 (+4.01%)
NFLX   184.41 (+2.48%)
S&P 500   3,816.93 (-0.22%)
DOW   30,864.58 (-0.75%)
QQQ   285.47 (+1.18%)
AAPL   141.21 (+1.64%)
MSFT   262.12 (+0.98%)
META   167.32 (+4.56%)
GOOGL   2,261.28 (+3.98%)
AMZN   113.59 (+3.68%)
TSLA   695.28 (+1.98%)
NVDA   148.86 (+2.50%)
NIO   22.04 (+3.18%)
BABA   118.48 (+2.14%)
AMD   74.77 (+1.49%)
MU   56.67 (+5.63%)
CGC   2.66 (-5.34%)
T   21.12 (-0.89%)
GE   61.74 (-2.83%)
F   11.11 (-1.86%)
DIS   96.98 (+0.87%)
AMC   12.62 (-6.73%)
PFE   51.34 (-1.85%)
PYPL   74.26 (+4.01%)
NFLX   184.41 (+2.48%)
S&P 500   3,816.93 (-0.22%)
DOW   30,864.58 (-0.75%)
QQQ   285.47 (+1.18%)
AAPL   141.21 (+1.64%)
MSFT   262.12 (+0.98%)
META   167.32 (+4.56%)
GOOGL   2,261.28 (+3.98%)
AMZN   113.59 (+3.68%)
TSLA   695.28 (+1.98%)
NVDA   148.86 (+2.50%)
NIO   22.04 (+3.18%)
BABA   118.48 (+2.14%)
AMD   74.77 (+1.49%)
MU   56.67 (+5.63%)
CGC   2.66 (-5.34%)
T   21.12 (-0.89%)
GE   61.74 (-2.83%)
F   11.11 (-1.86%)
DIS   96.98 (+0.87%)
AMC   12.62 (-6.73%)
PFE   51.34 (-1.85%)
PYPL   74.26 (+4.01%)
NFLX   184.41 (+2.48%)
NASDAQ:MDGL

Madrigal Pharmaceuticals Stock Forecast, Price & News

$77.35
+3.76 (+5.11%)
(As of 07/5/2022 03:07 PM ET)
Add
Compare
Today's Range
$72.32
$78.01
50-Day Range
$58.04
$84.65
52-Week Range
$52.33
$105.93
Volume
7,129 shs
Average Volume
184,343 shs
Market Capitalization
$1.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$167.43

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
116.5% Upside
$167.43 Price Target
Short Interest
Bearish
13.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.85mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($14.55) to ($11.17) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.31 out of 5 stars

Medical Sector

225th out of 1,428 stocks

Pharmaceutical Preparations Industry

109th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Madrigal Pharmaceuticals logo

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

MDGL Stock News Headlines

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 5.2%
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Up 8.3%
Madrigal: NASH Data In Q4 Is The Key
Madrigal Pharmaceuticals Q4 net loss widens Y/Y
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
71
Year Founded
2011

Company Calendar

Last Earnings
5/09/2022
Today
7/05/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$167.43
High Stock Price Forecast
$220.00
Low Stock Price Forecast
$111.00
Forecasted Upside/Downside
+116.5%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-241,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.47 per share

Miscellaneous

Free Float
12,022,000
Market Cap
$1.32 billion
Optionable
Optionable
Beta
1.20

Social Links















Madrigal Pharmaceuticals Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price forecast for 2022?

6 equities research analysts have issued 12-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL stock forecasts range from $111.00 to $220.00. On average, they predict Madrigal Pharmaceuticals' share price to reach $167.43 in the next twelve months. This suggests a possible upside of 116.5% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Madrigal Pharmaceuticals' stock performed in 2022?

Madrigal Pharmaceuticals' stock was trading at $84.74 on January 1st, 2022. Since then, MDGL shares have decreased by 8.7% and is now trading at $77.35.
View the best growth stocks for 2022 here
.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Madrigal Pharmaceuticals
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported ($3.36) earnings per share for the quarter, beating analysts' consensus estimates of ($3.75) by $0.39. During the same period in the previous year, the company posted ($3.32) EPS.
View Madrigal Pharmaceuticals' earnings history
.

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the following people:
  • Dr. Paul A. Friedman M.D., Chairman & CEO (Age 79, Pay $1.05M)
  • Dr. Rebecca A. Taub M.D., Founder, Chief Medical Officer, Pres of R&D and Director (Age 70, Pay $854.75k)
  • Mr. Alex G. Howarth, Sr. VP & CFO (Age 53, Pay $605.3k)
  • Mr. Brian J. Lynch J.D., Sr. VP & Gen. Counsel (Age 60, Pay $699.28k)
  • Mr. Remy Sukhija, Sr. VP & Chief Commercial Officer (Age 50, Pay $720.07k)
  • Dr. Kianoush Motesharei Ph.d., Sr. VP of Bus. & Corp. Devel. (Age 52)
  • Mr. Edward Chiang, Sr. VP of Clinical & Technical Operations
  • Mr. Thomas W. Hare, Sr. VP of Clinical Management
  • Dr. Robert E. Waltermire Ph.D., Chief Pharmaceutical Devel. Officer (Age 58)
  • Dr. Stephen Dodge M.B.A., Pharm.D., Sr. VP of Global Medical Affairs

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $77.35.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $1.32 billion. The biopharmaceutical company earns $-241,850,000.00 in net income (profit) each year or ($14.65) on an earnings per share basis.

How many employees does Madrigal Pharmaceuticals have?

Madrigal Pharmaceuticals employs 71 workers across the globe.

When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2011.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.